Urovant Sciences Ltd.
DelistedCIK 1740547fmd_0N47VW95Q575S0HJ2SGASZ5W0VManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Dec 31, 2020, 15 periods
Latest annual · FY2020
Millions- Net income
- (147)
Latest quarter · Q4 FY2020
Millions- Net income
- (47)
Urovant Sciences Ltd. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2020 | FY2019 | Change | Source |
|---|---|---|---|---|
| Net income | -$146.7 million | -$111.3 million | 10-K 2020-06-19 · proof | |
| Cash from operating activities | -$102.1 million | -$109 million | 10-K 2020-06-19 · proof | |
| Total assets | $108.9 million | $147.6 million | -26.2% | 10-Q 2021-02-12 · proof |
| Total liabilities | $254.5 million | $152 million | +67.4% | 10-Q 2021-02-12 · proof |
| Cash and cash equivalents | $71.3 million | $131.9 million | -46% | 10-Q 2021-02-12 · proof |
- What was Urovant Sciences Ltd.'s net income in fiscal 2020?
- Urovant Sciences Ltd. reported net income of -$146.7 million for fiscal 2020 (the year ended Mar 31, 2020), against -$111.3 million the year before. Source: the 10-K filed with the SEC on Jun 19, 2020. SEC
- What was Urovant Sciences Ltd.'s cash from operating activities in fiscal 2020?
- Urovant Sciences Ltd. reported cash from operating activities of -$102.1 million for fiscal 2020 (the year ended Mar 31, 2020), against -$109 million the year before. Source: the 10-K filed with the SEC on Jun 19, 2020. SEC
- What are Urovant Sciences Ltd.'s total assets?
- As of Dec 31, 2020, Urovant Sciences Ltd. reported total assets of $108.9 million, against $147.6 million a year earlier (-26.2%). Source: the 10-Q filed with the SEC on Feb 12, 2021. SEC
- What are Urovant Sciences Ltd.'s total liabilities?
- As of Dec 31, 2020, Urovant Sciences Ltd. reported total liabilities of $254.5 million, against $152 million a year earlier (+67.4%). Source: the 10-Q filed with the SEC on Feb 12, 2021. SEC
- What are Urovant Sciences Ltd.'s cash and cash equivalents?
- As of Dec 31, 2020, Urovant Sciences Ltd. reported cash and cash equivalents of $71.3 million, against $131.9 million a year earlier (-46%). Source: the 10-Q filed with the SEC on Feb 12, 2021. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1740547&period_type=annual&limit=5"Information only, not investment advice.